STP-100

**STP-100** is an investigational precision oncology **antibody-drug conjugate** being developed by **Stipple Bio**. Publicly available company and financing materials describe it as a novel ADC that uses **tumor-specific binders** identified through Stipple Bio's **Pointillist Platform** to recognize tumor-specific cell-surface epitopes, with the stated goal of improving therapeutic index and reducing **on-target off-tumor toxicity** relative to conventional targeted cancer therapeutics. The specific molecular target, payload, linker, cancer indication, route, and dosing details have not been publicly disclosed as of the available sources, but the asset is described as the company's lead program and was expected to enter early clinical studies in **early 2027**.